• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of Directors

    2/15/22 8:25:00 AM ET
    $CI
    $LUCD
    $PAVM
    Medical Specialities
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $CI alert in real time by email

    PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors. Ms. Harvey will serve as a member of the Company's Audit and Compensation Committees.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220215005417/en/

    PAVmed appoints Joan Harvey to its Board of Directors. (Photo: Business Wire)

    PAVmed appoints Joan Harvey to its Board of Directors. (Photo: Business Wire)

    "Ms. Harvey brings a wealth of health care experience, strong track record in strategic and business development, and deep financial acumen to our board," said Lishan Aklog M.D., PAVmed's chairman and chief executive officer. "She shares our passion for applying innovative technologies and care models to improve health outcomes, and her contributions will be invaluable as we drive commercial growth, expand our clinical services—including our network of diagnostic test centers—and partner with payors."

    "PAVmed's groundbreaking health technologies combined with their strong clinical and research teams have tremendous potential to propel the health care industry forward," said Ms. Harvey. "Their products have the ability to transform how we prevent, diagnose, and treat some of the most complex and debilitating diseases. I look forward to contributing to PAVmed's ongoing success and transformation into a leading global medical technology company."

    Ms. Harvey has more than two decades of health care experience serving in a variety of leadership roles dedicated to improving whole person health and advocating for patients. She is the president of Care Solutions for Evernorth, Cigna Corporation's (NYSE:CI) health services business. In this role, she oversees Evernorth's medical, behavioral, and pharmacy clinical programs to meet the diverse needs of health plans, employers, government organizations—and the people they serve.

    Prior to joining Evernorth, Ms. Harvey served in senior leadership roles at Cigna, Medco Health Solutions Inc., WellPoint 360 Health. a subsidiary of Anthem, Inc., American Imaging Management, and Oxford Health Plans, LLC, a subsidiary of UnitedHealth Group. She is a founding member of the Disease Management Association of America, and author of "Asthma Disease Management in the 21st Century" for the Managed Care Handbook: Best Practices in Medical Management. Ms. Harvey holds a Master of Business Administration from the American Graduate School of International Management and a Bachelor's degree in International Relations from Bates College.

    About PAVmed

    PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc. (NASDAQ:LUCD), markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. PAVmed's CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome is currently in limited commercial release. The product pipeline also includes the EsoCure™ Esophageal Ablation Device with Caldus™ Technology, which complements EsoGuard and EsoCheck, the NextFlo™ Intravenous Infusion Set, the PortIO™ Implantable Intraosseous Vascular Access Device, novel pediatric ear tubes, mechanical circulatory support technology and glucose monitoring. For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and Instagram.

    Forward-Looking Statements

    This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; PAVmed's Series W and Series Z warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's and products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. In addition, PAVmed has been monitoring the COVID-19 pandemic and the pandemic's impact on PAVmed's businesses. PAVmed expects the significance of the COVID-19 pandemic, including the extent of its effect on its financial and operational results, to be dictated by, among other things, the success of efforts to contain the pandemic and the impact of such efforts on PAVmed's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item IA, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report filed with the Securities and Exchange Commission. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005417/en/

    Get the next $CI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CI
    $LUCD
    $PAVM

    CompanyDatePrice TargetRatingAnalyst
    The Cigna Group
    $CI
    2/6/2025$323.00Outperform → Mkt Perform
    Bernstein
    The Cigna Group
    $CI
    6/26/2024$400.00Overweight
    Piper Sandler
    The Cigna Group
    $CI
    5/30/2024$388.00Outperform
    Robert W. Baird
    The Cigna Group
    $CI
    3/6/2024$393.00Overweight
    Barclays
    The Cigna Group
    $CI
    2/5/2024$334.00 → $372.00Neutral → Overweight
    Cantor Fitzgerald
    The Cigna Group
    $CI
    2/5/2024$327.00 → $354.00Sector Perform → Outperform
    RBC Capital Mkts
    The Cigna Group
    $CI
    2/1/2024$355.00 → $370.00Hold → Buy
    Deutsche Bank
    The Cigna Group
    $CI
    1/4/2024$330.00 → $372.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $CI
    $LUCD
    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • The Cigna Group Reports Strong First Quarter 2025 Results, Raises 2025 Outlook

      Total revenues for the first quarter 2025 increased 14% to $65.5 billionShareholders' net income for the first quarter 2025 was $1.3 billion, or $4.85 per shareAdjusted income from operations1 for the first quarter 2025 was $1.8 billion, or $6.74 per share2025 adjusted income from operations1,2 increased to at least $29.60 per share2BLOOMFIELD, Conn., May 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported strong first quarter 2025 results, reflecting growth and focused execution across its diversified portfolio of businesses. "We are buildin

      5/2/25 6:00:00 AM ET
      $CI
      Medical Specialities
      Health Care
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $CI
    $LUCD
    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Cigna Group downgraded by Bernstein with a new price target

      Bernstein downgraded The Cigna Group from Outperform to Mkt Perform and set a new price target of $323.00

      2/6/25 7:05:01 AM ET
      $CI
      Medical Specialities
      Health Care
    • Piper Sandler initiated coverage on The Cigna Group with a new price target

      Piper Sandler initiated coverage of The Cigna Group with a rating of Overweight and set a new price target of $400.00

      6/26/24 7:28:18 AM ET
      $CI
      Medical Specialities
      Health Care
    • Robert W. Baird initiated coverage on The Cigna Group with a new price target

      Robert W. Baird initiated coverage of The Cigna Group with a rating of Outperform and set a new price target of $388.00

      5/30/24 7:35:19 AM ET
      $CI
      Medical Specialities
      Health Care

    $CI
    $LUCD
    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wiseman Eric C was granted 638 shares, increasing direct ownership by 3% to 23,158 units (SEC Form 4)

      4 - Cigna Group (0001739940) (Issuer)

      4/25/25 4:33:03 PM ET
      $CI
      Medical Specialities
      Health Care
    • Director Ross Kimberly A. was granted 638 shares, increasing direct ownership by 16% to 4,512 units (SEC Form 4)

      4 - Cigna Group (0001739940) (Issuer)

      4/25/25 4:33:00 PM ET
      $CI
      Medical Specialities
      Health Care
    • Director Zarcone Donna F was granted 638 shares, increasing direct ownership by 2% to 26,735 units (SEC Form 4)

      4 - Cigna Group (0001739940) (Issuer)

      4/25/25 4:33:04 PM ET
      $CI
      Medical Specialities
      Health Care

    $CI
    $LUCD
    $PAVM
    SEC Filings

    See more
    • SEC Form DEFA14A filed by PAVmed Inc.

      DEFA14A - PAVmed Inc. (0001624326) (Filer)

      5/9/25 4:00:05 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by The Cigna Group

      144 - Cigna Group (0001739940) (Subject)

      5/8/25 4:11:59 PM ET
      $CI
      Medical Specialities
      Health Care
    • SEC Form 144 filed by The Cigna Group

      144 - Cigna Group (0001739940) (Subject)

      5/7/25 5:13:55 PM ET
      $CI
      Medical Specialities
      Health Care

    $CI
    $LUCD
    $PAVM
    Financials

    Live finance-specific insights

    See more
    • The Cigna Group Reports Strong First Quarter 2025 Results, Raises 2025 Outlook

      Total revenues for the first quarter 2025 increased 14% to $65.5 billionShareholders' net income for the first quarter 2025 was $1.3 billion, or $4.85 per shareAdjusted income from operations1 for the first quarter 2025 was $1.8 billion, or $6.74 per share2025 adjusted income from operations1,2 increased to at least $29.60 per share2BLOOMFIELD, Conn., May 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported strong first quarter 2025 results, reflecting growth and focused execution across its diversified portfolio of businesses. "We are buildin

      5/2/25 6:00:00 AM ET
      $CI
      Medical Specialities
      Health Care
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $CI
    $LUCD
    $PAVM
    Leadership Updates

    Live Leadership Updates

    See more
    • PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

      Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements.  As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain

      9/16/24 4:30:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • The Cigna Group's "Community Vitality Project" Donates $75,000 to Nonprofits through Program Encouraging Fitness and Community Engagement

      As part of the company's initiative, thousands of employees logged 280,000 minutes of exercise over nine days Cigna leaders biked to Hartford, Conn.'s Dunkin' Park to host Boys & Girls Clubs members for a Yard Goats baseball game, with surprise appearances by UConn basketball coach and playersBLOOMFIELD, Conn., Sept. 9, 2024 /PRNewswire/ -- The Cigna Group (NYSE:CI) put out a challenge to its workforce this summer, inviting colleagues to join its first-ever Community Vitality Project, a nine-day challenge combining fun, fitness and fundraising. By logging more than 280,000 minutes of fitness activities and awarding their minutes spent moving, The Cigna Group employees helped determine how to

      9/9/24 7:00:00 AM ET
      $CI
      Medical Specialities
      Health Care
    • Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

      Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing

      5/7/24 7:39:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $CI
    $LUCD
    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

      SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

      12/12/24 4:30:32 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      11/14/24 10:02:46 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by The Cigna Group

      SC 13G - Cigna Group (0001739940) (Subject)

      11/12/24 9:55:14 AM ET
      $CI
      Medical Specialities
      Health Care